Deep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsies.

Lipkova, Jana; Chen, Tiffany Y; Lu, Ming Y; Chen, Richard J; Shady, Maha; Williams, Mane; Wang, Jingwen; Noor, Zahra; Mitchell, Richard N; Turan, Mehmet; Coskun, Gulfize; Yilmaz, Funda; Demir, Derya; Nart, Deniz; Basak, Kayhan; Turhan, Nesrin; Ozkara, Selvinaz; Banz, Yara; Odening, Katja E and Mahmood, Faisal (2022). Deep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsies. Nature medicine, 28(3), pp. 575-582. Springer Nature 10.1038/s41591-022-01709-2

Text s41591-022-01709-2.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (10MB) | Request a copy

Endomyocardial biopsy (EMB) screening represents the standard of care for detecting allograft rejections after heart transplant. Manual interpretation of EMBs is affected by substantial interobserver and intraobserver variability, which often leads to inappropriate treatment with immunosuppressive drugs, unnecessary follow-up biopsies and poor transplant outcomes. Here we present a deep learning-based artificial intelligence (AI) system for automated assessment of gigapixel whole-slide images obtained from EMBs, which simultaneously addresses detection, subtyping and grading of allograft rejection. To assess model performance, we curated a large dataset from the United States, as well as independent test cohorts from Turkey and Switzerland, which includes large-scale variability across populations, sample preparations and slide scanning instrumentation. The model detects allograft rejection with an area under the receiver operating characteristic curve (AUC) of 0.962; assesses the cellular and antibody-mediated rejection type with AUCs of 0.958 and 0.874, respectively; detects Quilty B lesions, benign mimics of rejection, with an AUC of 0.939; and differentiates between low-grade and high-grade rejections with an AUC of 0.833. In a human reader study, the AI system showed non-inferior performance to conventional assessment and reduced interobserver variability and assessment time. This robust evaluation of cardiac allograft rejection paves the way for clinical trials to establish the efficacy of AI-assisted EMB assessment and its potential for improving heart transplant outcomes.

Interest & Impact

Downloads

2 since deposited on 23 Mar 2022
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item